[Experimental study on anti-atherosclerotic effect of compatibility of active components of danshen and shanzha].
OBJECTIVE
To investigate the effect of active components of Danshen and Shanzha of different matching proportions on atherosclerosis (AS), in the expectation of obtaining the optimum combination method.


METHODS
Atherosclerotic rats were fed with high fat diet, and injected with vitamin D3 and ovalbumin. Aqueous extracts of Danshen (DSA) and Shanzha (SZA) and lipophilic extracts of danshen (DSL) were adopted for a low, medium and high-dose orthogonal experiment, to observe the effect of their different matching proportions on lipid level, oxidative stress, endothelial function and inflammatory reaction. The principal component analysis and cluster analysis were adopted for the multi-objective optimization of experimental results.


RESULTS
Compared with the model group, all of samples with different proportions of DSA, DSL and SZA showed effect in lowering lipid level, scavenging free radicals, reducing endothelial dysfunction and inhibiting inflammation. According to the variance analysis, DSA2-SZA2-DSL1, DSA3-SZA2-DSL1, DSA3-SZA3 -DSL3 and DSA3-SZA1-DSL1 were the optimal proportions for lowering lipid level, scavenging free radicals, reducing endothelial dysfunction and inhibiting inflammation, respectively. According to the results of the multi-objective optimization, DSA2-SZA1-DSL2 was the optimal proportions of anti-AS.


CONCLUSIONS
All of active components of Danshen and Shanzha of different matching proportions show the anti-AS effect in rats to varying degrees, but with different focus in different matching proportions.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. riskeen@sina.com
Jian-Yong
JY
Zhang
Ren-Yi
RY
Yan
Lan
L
Wang
Jian-Lu
JL
Wang
Wan-Dan
WD
Wang
Rui
R
Hou
Hong-Liang
HL
Liu
Hong-Jun
HJ
Yang
Ri-Xin
RX
Liang
Bin
B
Yang
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D050197:Atherosclerosis / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008297:Male; D010618:Phenanthrolines / Q000627:therapeutic use; D008517:Phytotherapy; D051381:Rats; D027561:Salvia miltiorrhiza / Q000737:chemistry
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D004365:Drugs, Chinese Herbal; D008055:Lipids; D010618:Phenanthrolines; C544212:shanzha; C028972:dan-shen root extract